Promoter polymorphism of the matrix metalloproteinase 3 gene is associated with regurgitation and left ventricular remodelling in mitral valve prolapse patients

European Journal of Heart Failure

Volumn 9, Issue 10, 2007, Pages 1010-1017

  Oceandy, Delvac ^a   Yusoff, Rahal ^b   Baudoin, Florence M ^a   Neyses, Ludwig ^a   Ray, Simon G ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b WYTHENSHAWE HOSPITAL   (United Kingdom)

Author keywords

Echocardiography; Genetics; Mitral valve; Regurgitation; Remodelling

Indexed keywords

INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; STROMELYSIN;

ADULT; AGED; ALLELE; ARTICLE; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; DNA POLYMORPHISM; ECHOCARDIOGRAPHY; FEMALE; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEART LEFT VENTRICLE; HEART VENTRICLE REMODELING; HEREDITY; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE; MITRAL VALVE PROLAPSE; MITRAL VALVE REGURGITATION; MOLECULAR CLONING; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION;

AGED; ALLELES; CASE-CONTROL STUDIES; FEMALE; HEART VENTRICLES; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; MITRAL VALVE INSUFFICIENCY; MITRAL VALVE PROLAPSE; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); VENTRICULAR REMODELING;

EID: 34548825965     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2007.07.005     Document Type: Article

References (31)

1. Freed L.A., Levy D., Levine R.A., et al. Prevalence and clinical outcome of mitral-valve prolapse. N Engl J Med 341 (1999) 1-7
2. Levy D., and Savage D. Prevalence and clinical features of mitral valve prolapse. Am Heart J 113 (1987) 1281-1290
3. Disse S., Abergel E., Berrebi A., et al. Mapping of a first locus for autosomal dominant myxomatous mitral-valve prolapse to chromosome 16p11.2-p12.1. Am J Hum Genet 65 (1999) 1242-1251
4. Freed L.A., Acierno Jr. J.S., Dai D., et al. A locus for autosomal dominant mitral valve prolapse on chromosome 11p15.4. Am J Hum Genet 72 (2003) 1551-1559
5. Nesta F., Leyne M., Yosefy C., et al. New locus for autosomal dominant mitral valve prolapse on chromosome 13: clinical insights from genetic studies. Circulation 112 (2005) 2022-2030
6. Chou H.T., Hung J.S., Chen Y.T., Wu J.Y., and Tsai F.J. Association between COL3A1 collagen gene exon 31 polymorphism and risk of floppy mitral valve/mitral valve prolapse. Int J Cardiol 95 (2004) 299-305
7. Chou H.T., Shi Y.R., Hsu Y., and Tsai F.J. Association between fibrillin-1 gene exon 15 and 27 polymorphisms and risk of mitral valve prolapse. J Heart Valve Dis 12 (2003) 475-481
8. Szombathy T., Janoskuti L., Szalai C., et al. Angiotensin II type 1 receptor gene polymorphism and mitral valve prolapse syndrome. Am Heart J 139 (2000) 101-105
9. Spinale F.G. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res 90 (2002) 520-530
10. Rutter J.L., Mitchell T.I., Buttice G., et al. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res 58 (1998) 5321-5325
11. Ye S., Eriksson P., Hamsten A., Kurkinen M., Humphries S.E., and Henney A.M. Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J Biol Chem 271 (1996) 13055-13060
12. Schiller N.B., Shah P.M., Crawford M., et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-dimensional Echocardiograms. J Am Soc Echocardiogr 2 (1989) 358-367
13. Rokey R., Sterling L.L., Zoghbi W.A., et al. Determination of regurgitant fraction in isolated mitral or aortic regurgitation by pulsed Doppler two-dimensional echocardiography. J Am Coll Cardiol 7 (1986) 1273-1278
14. Devereux R.B., Alonso D.R., Lutas E.M., et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 57 (1986) 450-458
15. Dunleavey L., Beyzade S., and Ye S. Rapid genotype analysis of the stromelysin gene 5A/6A polymorphism. Atherosclerosis 151 (2000) 587-589
16. Hinoda Y., Okayama N., Takano N., et al. Association of functional polymorphisms of matrix metalloproteinase (MMP)-1 and MMP-3 genes with colorectal cancer. Int J Cancer 102 (2002) 526-529
17. Beyzade S., Zhang S., Wong Y.K., Day I.N., Eriksson P., and Ye S. Influences of matrix metalloproteinase-3 gene variation on extent of coronary atherosclerosis and risk of myocardial infarction. J Am Coll Cardiol 41 (2003) 2130-2137
18. Quinones S., Saus J., Otani Y., Harris Jr. E.D., and Kurkinen M. Transcriptional regulation of human stromelysin. J Biol Chem 264 (1989) 8339-8344
19. Ye S. Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. Matrix Biol 19 (2000) 623-629
20. Spinale F.G., Coker M.L., Thomas C.V., Walker J.D., Mukherjee R., and Hebbar L. Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function. Circ Res 82 (1998) 482-495
21. Beilby J.P., Chapman C.M., Palmer L.J., McQuillan B.M., Thompson P.L., and Hung J. Stromelysin-1 (MMP-3) gene 5A/6A promoter polymorphism is associated with blood pressure in a community population. J Hypertens 23 (2005) 537-542
22. Terashima M., Akita H., Kanazawa K., et al. Stromelysin promoter 5A/6A polymorphism is associated with acute myocardial infarction. Circulation 99 (1999) 2717-2719
23. Medley T.L., Kingwell B.A., Gatzka C.D., Pillay P., and Cole T.J. Matrix metalloproteinase-3 genotype contributes to age-related aortic stiffening through modulation of gene and protein expression. Circ Res 92 (2003) 1254-1261
24. Mizon-Gerard F., de Groote P., Lamblin N., et al. Prognostic impact of matrix metalloproteinase gene polymorphisms in patients with heart failure according to the aetiology of left ventricular systolic dysfunction. Eur Heart J 25 (2004) 688-693
25. Dreger S.A., Taylor P.M., Allen S.P., and Yacoub M.H. Profile and localization of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in human heart valves. J Heart Valve Dis 11 (2002) 875-880 [discussion 880]
26. Nagatomo Y., Carabello B.A., Coker M.L., et al. Differential effects of pressure or volume overload on myocardial MMP levels and inhibitory control. Am J Physiol Heart Circ Physiol 278 (2000) H151-H161
27. Coker M.L., Thomas C.V., Clair M.J., et al. Myocardial matrix metalloproteinase activity and abundance with congestive heart failure. Am J Physiol 274 (1998) H1516-H1523
28. Ahmed S.H., Clark L.L., Pennington W.R., et al. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 113 (2006) 2089-2096
29. Ducharme A., Frantz S., Aikawa M., et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 106 (2000) 55-62
30. Kim H.E., Dalal S.S., Young E., Legato M.J., Weisfeldt M.L., and D'Armiento J. Disruption of the myocardial extracellular matrix leads to cardiac dysfunction. J Clin Invest 106 (2000) 857-866
31. Bellenger N.G., Burgess M.I., Ray S.G., et al. Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable?. Eur Heart J 21 (2000) 1387-1396